These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

753 related articles for article (PubMed ID: 16943530)

  • 21. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
    J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prognostic Value of Morphology and Hans Classification in Diffuse Large B Cell Lymphoma].
    Wang KL; Chen C; Shi PF; Yu JH; Tan JF; Qian SX; Gao DQ; Chen K; Liu LR; Xie YP; Xu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1079-1085. PubMed ID: 30111411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of immunohistochemical subtypes in diffuse large B-cell lymphoma and its impact on survival.
    Dwivedi A; Mehta A; Solanki P
    Indian J Pathol Microbiol; 2015; 58(4):453-8. PubMed ID: 26549066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Nodal versus extranodal diffuse large B-cell lymphoma: comparison of clinicopathologic features, immunophenotype and prognosis].
    Lu JB; Li XQ; Zhang PH; Zhou XY; Zhang TM; Li XM; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):470-3. PubMed ID: 17845761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.
    Cozzolino I; Varone V; Picardi M; Baldi C; Memoli D; Ciancia G; Selleri C; De Rosa G; Vetrani A; Zeppa P
    Cancer Cytopathol; 2016 Feb; 124(2):135-43. PubMed ID: 26414904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
    Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
    Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival.
    Haarer CF; Roberts RA; Frutiger YM; Grogan TM; Rimsza LM
    Arch Pathol Lab Med; 2006 Dec; 130(12):1819-24. PubMed ID: 17149956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin.
    Lin CH; Kuo KT; Chuang SS; Kuo SH; Chang JH; Chang KC; Hsu HC; Tien HF; Cheng AL
    Clin Cancer Res; 2006 Feb; 12(4):1152-6. PubMed ID: 16489068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Significance of myc gene rearrangement and its correlation with prognosis in diffuse large B cell lymphoma].
    Zhang HW; Chen ZW; He JX; Zheng YP; Han WE; Zhao ZQ; Bai W; Wang JF
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):119-23. PubMed ID: 23714666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
    Seki R; Ohshima K; Fujisaki T; Uike N; Kawano F; Gondo H; Makino S; Eto T; Moriuchi Y; Taguchi F; Kamimura T; Tsuda H; Ogawa R; Shimoda K; Yamashita K; Suzuki K; Suzushima H; Tsukazaki K; Higuchi M; Utsunomiya A; Iwahashi M; Imamura Y; Tamura K; Suzumiya J; Yoshida M; Abe Y; Matsumoto T; Okamura T
    Cancer Sci; 2009 Oct; 100(10):1842-7. PubMed ID: 19656156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
    Wang W; Hu S; Lu X; Young KH; Medeiros LJ
    Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunophenotype classification and therapeutic outcomes of Chinese primary gastrointestinal diffuse large B-cell lymphoma.
    Zhang Z; Shen Y; Shen D; Ni X
    BMC Gastroenterol; 2012 Jun; 12():77. PubMed ID: 22726454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
    Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
    Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
    Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
    Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression and Clinical Significance of Ki-67, CD10, BCL6, MUM1, c-MYC, and EBV in Diffuse Large B Cell Lymphoma Patients.
    Sadeghipour A; Taha SR; Shariat Zadeh M; Kosari F; Babaheidarian P; Fattahi F; Abdi N; Tajik F
    Appl Immunohistochem Mol Morphol; 2024 Aug; 32(7):309-321. PubMed ID: 38872345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expression of CD68, cyclin D1 and rearrangement of bcl-6 gene are adverse prognostic factors in diffuse large B-cell lymphoma].
    Liang X; Wang J; Bai W; Sun R
    Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):559-64. PubMed ID: 26705179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High levels of topoisomerase IIalpha protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment.
    Pentheroudakis G; Goussia A; Voulgaris E; Nikolaidis K; Ioannidou E; Papoudou-Bai A; Grepi K; Kanavaros P; Pavlidis N; Bai M
    Leuk Lymphoma; 2010 Jul; 51(7):1260-8. PubMed ID: 20497003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different predictive values of interim
    Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
    Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prevalence of germinal center B-cell-like and non-germinal center B-cell-like types of diffuse large B-cell lymphoma in Shanghai, China].
    Chen Y; Chen H; Fu K; Zhu XZ; Irons R
    Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):313-8. PubMed ID: 20654154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.